What is the simple formula to calculate half-life (t1/2) of a substance in a patient with potential renal or hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Simple Formula to Calculate Half-Life

The most straightforward formula to calculate half-life (t½) is: t½ = 0.693 / k, where k is the elimination rate constant. 1

Basic Calculation Methods

Standard Formula

  • Half-life equals 0.693 (natural log of 2) divided by the elimination rate constant (k): t½ = 0.693/k 1
  • The elimination rate constant k can be derived from the slope of the natural log of plasma concentration versus time 1
  • This formula applies to first-order elimination kinetics, which describes most drugs 1, 2

Alternative Calculation from Clearance

  • Half-life can also be calculated as: t½ = (0.693 × Volume of Distribution) / Clearance 1
  • This relationship is particularly useful when clearance and volume of distribution are known 1

Critical Adjustments for Renal or Hepatic Impairment

Renal Impairment Considerations

  • For renally eliminated drugs, reduced glomerular filtration rate (GFR) directly prolongs half-life 1
  • Creatinine clearance (CrCl) serves as a proxy for renal function and affects drug elimination 1
  • Example: Dabigatran has a half-life of 14-17 hours with normal renal function (CrCl ≥80 mL/min), but increases to 16-18 hours with moderate impairment (CrCl 30-50 mL/min) 1, 3
  • Use the CKD-EPI equation for most accurate eGFR estimation in adults, as it outperforms creatinine-based equations alone 1

Hepatic Impairment Considerations

  • For drugs with high hepatic extraction (diltiazem, lidocaine, metoprolol, propranolol, verapamil), reduced hepatic blood flow prolongs half-life 1
  • Drugs with low intrinsic clearance (like warfarin) depend more on hepatic enzyme activity than blood flow 1
  • Phase I metabolism (CYP450-mediated) decreases 20-50% with age and hepatic disease, increasing half-life of highly metabolized drugs 1

Practical Clinical Application

Bedside Estimation

  • For clinical purposes, if you know the dosing interval at steady-state where peak concentration is twice the first-dose peak, this equals the "operational multiple dosing half-life" 4, 5
  • This operational half-life is often more clinically relevant than terminal half-life for predicting drug accumulation 4, 5

Single Sample Method

  • When only one blood sample is available, half-life can be estimated if the sample is drawn at or after three half-lives post-dose 6, 7
  • This approach is particularly valuable in critically ill patients where multiple sampling poses risks 6, 7
  • The later the sampling point, the more accurate the half-life estimate 7

Common Pitfalls to Avoid

  • Do not assume terminal half-life predicts drug accumulation at steady-state—the operational multiple dosing half-life is often significantly shorter 4, 5
  • Do not rely solely on serum creatinine in elderly patients—reduced muscle mass can mask renal impairment, leading to underestimation of half-life prolongation 1
  • Do not use population average half-lives for dose adjustments in patients with organ impairment—calculate patient-specific values when possible 6
  • For two-compartment models, MRT (mean residence time) may be greater or less than half-life depending on the fraction of drug eliminated in the distribution phase 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.